Duloxetine
Depressive Disorder
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Huazhong University of Science and Technology
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
71High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06968624CT.gov Ketamine for Postherpetic Neuralgia With Depression | — | Not Yet Recruiting | — | — | — |
NCT06259526CT.gov A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression | — | Completed | — | — | — |
NCT05930912CT.gov Psychiatric Orders in Psychoanalytic Treatment of ASD | — | Unknown | — | — | — |
NCT03852160CT.gov A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression | — | Withdrawn | — | — | — |
NCT03434041CT.gov A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02493868CT.gov A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02655354CT.gov A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | — | Completed | — | — | — |
NCT02422186CT.gov A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02374567CT.gov Pharmacovigilance in Gerontopsychiatric Patients | — | Terminated | — | — | — |
NCT01360866CT.gov Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT01369095CT.gov Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression | — | Completed | — | — | — |
NCT01309945CT.gov Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression | — | Completed | — | — | — |
NCT00366652CT.gov Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects | — | Completed | — | — | — |
NCT00200902CT.gov Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression | — | Completed | — | — | — |
NCT00177671CT.gov Antidepressant Medication Plus Donepezil for Treating Late-life Depression | — | Completed | — | — | — |
NCT00073411CT.gov Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Duloxetine (this asset) | Huazhong University of Science and Technology | Approved | BBB · 72 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Saredutant | Sanofi | P3 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | VA Office of Research and Development | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| Paroxetine | Brigham and Women's Hospital | P4 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Duloxetine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetic Neuropathy | — | P4 | A · 81 |
| Fibromyalgia | — | P4 | BBB · 74 |
| Osteoarthritis | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Duloxetine in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/duloxetine-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →